Search Result

Results for "

restenosis

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Akt (1) Apoptosis (5) Bcl-2 Family (1) c-Myc (1) CFTR (4) COX (4) Dopamine Transporter (1) Drug Derivative (1) Endoplasmic Reticulum Oxidoreductase 1 (ERO1) (4) Endothelin Receptor (2) ERK (1) FLT3 (1) FOXO (1) Heme Oxygenase (HO) (1) JNK (1) Neprilysin (1) p38 MAPK (1) PDGFR (3) Phosphodiesterase (PDE) (2) Prostaglandin Receptor (2) Protease Activated Receptor (PAR) (2) Reference Standards (3) Serotonin Transporter (1) Tyrosinase (1)
By Research Areas:	Cancer (4) Cardiovascular Disease (9) Inflammation/Immunology (5) Metabolic Disease (4) Neurological Disease (2)

By Targets:

Akt (1)

Apoptosis (5)

Bcl-2 Family (1)

c-Myc (1)

CFTR (4)

COX (4)

Dopamine Transporter (1)

Drug Derivative (1)

Endoplasmic Reticulum Oxidoreductase 1 (ERO1) (4)

Endothelin Receptor (2)

ERK (1)

FLT3 (1)

FOXO (1)

Heme Oxygenase (HO) (1)

JNK (1)

Neprilysin (1)

p38 MAPK (1)

PDGFR (3)

Phosphodiesterase (PDE) (2)

Prostaglandin Receptor (2)

Protease Activated Receptor (PAR) (2)

Reference Standards (3)

Serotonin Transporter (1)

Tyrosinase (1)

By Research Areas:

Cancer (4)

Cardiovascular Disease (9)

Inflammation/Immunology (5)

Metabolic Disease (4)

Neurological Disease (2)

Inhibitors & Agonists

Natural
Products

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-B1153

Glafenine 4 Publications Verification Glafenin	COX CFTR Apoptosis Endoplasmic Reticulum Oxidoreductase 1 (ERO1)	Metabolic Disease Inflammation/Immunology
Glafenine (Glafenin) is a non-selective, non-steroidal anti-inflammatory drug-based COX-1/COX-2 inhibitor. Glafenine exerts anti-inflammatory, anti-proliferative and anti-cell migration effects by inhibiting the arachidonic acid metabolic pathway and reducing prostaglandin synthesis. Glafenine can induce cell cycle arrest in vascular smooth muscle cells and endothelial cells and reduce the synthesis of the extracellular matrix protein Tenascin. Glafenine can be used in the research of inflammatory-related diseases, vascular restenosis and cystic fibrosis (CF) .

HY-12424

Zotarolimus 4 Publications Verification ABT-578; A 179578	Drug Derivative	Cardiovascular Disease Inflammation/Immunology Cancer
Zotarolimus (ABT-578) is a derivative of Rapamycin (HY-10219), with anti-proliferative activity. Zotarolimus is an immunosuppressant. Zotarolimus is developed specifically for local delivery from stents for the prevention of coronary artery restenosis .

HY-N0863

Methyl protodioscin NSC-698790; Smilax saponin B	Bcl-2 Family Apoptosis Akt c-Myc ERK p38 MAPK JNK FOXO	Cancer
Methyl protodioscin (NSC-698790; Smilax saponin B) is a multi-target, selective, steroidal diglycoside inhibitor with antitumor activity that induces cell cycle arrest. The mechanism of action of Methyl protodioscin is complex, involving the induction of G2/M cell cycle arrest, regulation of the Bcl-2/Bax apoptotic pathway, inhibition of the Akt1/c-Myc axis and MAPK/ERK signaling, while simultaneously downregulating ADAM15 and inducing FOXO1 to reduce cholesterol synthesis. It also inhibits the JNK/c-Jun pathway, reducing the production of inflammatory factors (IL-6, TNF-α). Methyl protodioscin exhibits significant antitumor (inhibiting proliferation, migration, invasion, and inducing apoptosis), anti-inflammatory, and anti-restenosis activities. Methyl protodioscin can be used in research on lung cancer, prostate cancer, pancreatic cancer, and other tumors, as well as inflammatory diseases such as airway inflammation and enteritis .

HY-B1016

Trapidil AR-12008	PDGFR Phosphodiesterase (PDE) Prostaglandin Receptor	Cardiovascular Disease Neurological Disease
Trapidil (AR-12008) is an orally active vasodilator and antiplatelet agent. Trapidil antagonizes platelet-derived growth factor (PDGF), inhibits phosphodiesterase, thromboxane A₂ synthesis and pro-inflammatory cytokine production. Trapidil promotes prostacyclin biosynthesis, reduces lipid peroxidation, regulates nitric oxide metabolism, and inhibits cell proliferation and migration. Trapidil exerts tissue-protective effects, regulates bone turnover, and inhibits pyroptosis via the GPX3/Nrf2 pathway. Trapidil is applicable to research related to renal ischemia-reperfusion injury, chronic stable angina, restenosis, meningioma, diabetic cardiomyopathy and peripheral nerve crush injury .

HY-B1153A

Glafenine hydrochloride 4 Publications Verification Glafenin hydrochloride	COX CFTR Apoptosis Endoplasmic Reticulum Oxidoreductase 1 (ERO1)	Metabolic Disease Inflammation/Immunology
Glafenine (Glafenin) hydrochloride is a non-selective, non-steroidal anti-inflammatory drug-based COX-1/COX-2 inhibitor. Glafenine hydrochloride exerts anti-inflammatory, anti-proliferative and anti-cell migration effects by inhibiting the arachidonic acid metabolic pathway and reducing prostaglandin synthesis. Glafenine hydrochloride can induce cell cycle arrest in vascular smooth muscle cells and endothelial cells and reduce the synthesis of the extracellular matrix protein Tenascin. Glafenine hydrochloride can be used in the research of inflammatory-related diseases, vascular restenosis and cystic fibrosis (CF) .

HY-110019

Indatraline hydrochloride Lu 19-005	Serotonin Transporter Dopamine Transporter	Neurological Disease
Indatraline hydrochloride (Lu 19-005) is a non-selective monoamine transporter inhibitor that blocks the reuptake of neurotransmitters (dopamine, serotonin, and norepinephrine). Indatraline hydrochloride can be used for the research of antidepressive. Indatraline hydrochloride induces autophagy while simultaneously inhibiting cell proliferation. Indatraline hydrochloride may also serve to direct the development of new agents for autophagy-related diseases such as atherosclerosis or restenosis .

HY-B1153R

Glafenine (Standard) Glafenin (Standard)	COX CFTR Apoptosis Endoplasmic Reticulum Oxidoreductase 1 (ERO1) Reference Standards	Metabolic Disease Inflammation/Immunology
Glafenine (Standard) is the analytical standard of Glafenine. This product is intended for research and analytical applications. Glafenine (Glafenin) is a non-selective, non-steroidal anti-inflammatory drug-based COX-1/COX-2 inhibitor. Glafenine exerts anti-inflammatory, anti-proliferative and anti-cell migration effects by inhibiting the arachidonic acid metabolic pathway and reducing prostaglandin synthesis. Glafenine can induce cell cycle arrest in vascular smooth muscle cells and endothelial cells and reduce the synthesis of the extracellular matrix protein Tenascin. Glafenine can be used in the research of inflammatory-related diseases, vascular restenosis and cystic fibrosis (CF) .

HY-112350

AGL 2043	PDGFR FLT3	Cancer
AGL 2043 is an effective inhibitor of PDGFR (IC₅₀=0.8 μM) and TEL-PDGFR kinases, as well as FLT3 and KIT kinases. AGL 2043 can effectively inhibit porcine cardiac smooth muscle cell proliferation and balloon-induced vascular stenosis, and is suitable for development as an anti-restenotic and anticancer agent .

HY-15402

Edonentan BMS 207940	Endothelin Receptor	Cardiovascular Disease
Edonentan (BMS 207940) is an antagonist for endothelin receptor (ET_A receptor), with a K_i of 10 pM. Edonentan is metabolic stable, exhibits good pharmakokinetic characters in rats. Edonentan regulates the endothelin system, blocks the big Endothelin-induced pressor response in rats model .

HY-B1016R

Trapidil (Standard) AR-12008 (Standard)	Reference Standards PDGFR Phosphodiesterase (PDE) Prostaglandin Receptor	Cardiovascular Disease Cancer
Trapidil (Standard) (AR-12008 (Standard)) is the analytical standard of Trapidil (HY-B1016R). This product is intended for research and analytical applications. Trapidil (AR-12008) is an orally active vasodilator and antiplatelet agent. Trapidil antagonizes platelet-derived growth factor (PDGF), inhibits phosphodiesterase, thromboxane A2 synthesis and pro-inflammatory cytokine production. Trapidil promotes prostacyclin biosynthesis, reduces lipid peroxidation, regulates nitric oxide metabolism, and inhibits cell proliferation and migration. Trapidil exerts tissue-protective effects, regulates bone turnover, and inhibits pyroptosis via the GPX3/Nrf2 pathway. Trapidil is applicable to research related to renal ischemia-reperfusion injury, chronic stable angina, restenosis, meningioma, diabetic cardiomyopathy and peripheral nerve crush injury.

HY-143314

Protease-Activated Receptor-1 antagonist 2	Protease Activated Receptor (PAR)	Cardiovascular Disease
Protease-Activated Receptor-1 antagonist 2 is an orally active protease-activated receptor-1 (PAR-1) antagonist, with an IC₅₀ value of 7 nM. Protease-Activated Receptor-1 antagonist 2 has favorable pharmacokinetic properties which is useful in the research of cardiovascular disease (CVD), such as atherosclerosis and restenosis .

HY-U00336

NEP-IN-2	Neprilysin	Cardiovascular Disease
NEP-IN-2 is an inhibitor of neutral endopeptidase, used in the research of proliferation in atherosclerosis, restenosis.

HY-117644

L-749329 (Rac)-L-754142	Endothelin Receptor	Cardiovascular Disease
L-749329 ((Rac)-L-754142) is an ET_A and ET_B receptor antagonist, with K_is of 0.062 nM and 2.25 nM for ET_A and ET_B respectively. L-749329 inhibits ET-1-stimulated signaling .

HY-W424839

Probucol dithiobisphenol DTBP	Heme Oxygenase (HO)	Cardiovascular Disease
Probucol dithiobisphenol (DTBP) is the derivative of Probucol (HY-B0388). Probucol dithiobisphenol induces the production of heme oxygenase 1 (HO-1), and exhibits antioxidant activity. Probucol dithiobisphenol inhibits atherosclerotic lesions in Apoe ^−/− mice aorta, promotes re-endothelialization of aorta and inhibits restenosis in rabbit arterial injury models. Probucol dithiobisphenol is orally active .

HY-B1153AR

Glafenine hydrochloride (Standard) Glafenin hydrochloride (Standard)	COX CFTR Apoptosis Endoplasmic Reticulum Oxidoreductase 1 (ERO1) Reference Standards	Metabolic Disease Inflammation/Immunology
Glafenine (hydrochloride) (Standard) is the analytical standard of Glafenine (hydrochloride). This product is intended for research and analytical applications. Glafenine (Glafenin) hydrochloride is a non-selective, non-steroidal anti-inflammatory drug-based COX-1/COX-2 inhibitor. Glafenine hydrochloride exerts anti-inflammatory, anti-proliferative and anti-cell migration effects by inhibiting the arachidonic acid metabolic pathway and reducing prostaglandin synthesis. Glafenine hydrochloride can induce cell cycle arrest in vascular smooth muscle cells and endothelial cells and reduce the synthesis of the extracellular matrix protein Tenascin. Glafenine hydrochloride can be used in the research of inflammatory-related diseases, vascular restenosis and cystic fibrosis (CF) .

HY-182713

Tyrphostin AG-808	Tyrosinase	Others
Tyrphostin AG-808 is a protein tyrosine kinase inhibitor that does not reduce neointimal formation. Perivascular implantation of Tyrphostin AG-808 causes medial damage in rats .

HY-182573

RWJ-58259	Protease Activated Receptor (PAR)	Cardiovascular Disease
RWJ-58259 is a selective PAR-1 inhibitor with an IC₅₀ value of 0.15 μM. RWJ-58259 binds selectively to PAR-1, blocks the binding of tethered ligands, interferes with calcium mobilization and PAR-1-related cellular functions, and exhibits no PAR-1 agonist activity or thrombin proteolytic inhibitory activity. RWJ-58259 inhibits thrombin-induced platelet aggregation, calcium signaling and vascular smooth muscle cell proliferation, reduces neointimal thickness and arterial stenosis, and alleviates vascular occlusion and platelet deposition. RWJ-58259 can be used in the research of thrombotic diseases and vascular injury associated with acute coronary intervention .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-N0863

Methyl protodioscin NSC-698790; Smilax saponin B	Structural Classification other families Classification of Application Fields Plants Disease Research Fields Steroids Source Classification Cancer	Bcl-2 Family Apoptosis Akt c-Myc ERK p38 MAPK JNK FOXO
Methyl protodioscin (NSC-698790; Smilax saponin B) is a multi-target, selective, steroidal diglycoside inhibitor with antitumor activity that induces cell cycle arrest. The mechanism of action of Methyl protodioscin is complex, involving the induction of G2/M cell cycle arrest, regulation of the Bcl-2/Bax apoptotic pathway, inhibition of the Akt1/c-Myc axis and MAPK/ERK signaling, while simultaneously downregulating ADAM15 and inducing FOXO1 to reduce cholesterol synthesis. It also inhibits the JNK/c-Jun pathway, reducing the production of inflammatory factors (IL-6, TNF-α). Methyl protodioscin exhibits significant antitumor (inhibiting proliferation, migration, invasion, and inducing apoptosis), anti-inflammatory, and anti-restenosis activities. Methyl protodioscin can be used in research on lung cancer, prostate cancer, pancreatic cancer, and other tumors, as well as inflammatory diseases such as airway inflammation and enteritis .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Name
Email *

	Sorry, but the email address you supplied was invalid.

restenosis

Inhibitors & Agonists

NaturalProducts

Natural
Products